vs
Side-by-side financial comparison of CENTRAL PACIFIC FINANCIAL CORP (CPF) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $72.9M, roughly 1.2× CENTRAL PACIFIC FINANCIAL CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 6.0%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.7%).
Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CPF vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.9M | $86.8M |
| Net Profit | $20.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 28.4% | — |
| Revenue YoY | 6.0% | 17.7% |
| Net Profit YoY | 16.7% | — |
| EPS (diluted) | $0.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $76.3M | $86.8M | ||
| Q3 25 | $74.8M | $67.5M | ||
| Q2 25 | $72.8M | $60.0M | ||
| Q1 25 | $68.8M | $49.3M | ||
| Q4 24 | $58.4M | $73.7M | ||
| Q3 24 | $66.6M | $58.6M | ||
| Q2 24 | $64.0M | $31.1M |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $22.9M | — | ||
| Q3 25 | $18.6M | $-91.3M | ||
| Q2 25 | $18.3M | $-111.7M | ||
| Q1 25 | $17.8M | $-116.2M | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $13.3M | $-83.5M | ||
| Q2 24 | $15.8M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 37.0% | -84.7% | ||
| Q3 25 | 31.6% | -140.7% | ||
| Q2 25 | 32.8% | -189.8% | ||
| Q1 25 | 32.8% | -245.8% | ||
| Q4 24 | 23.0% | -117.5% | ||
| Q3 24 | 25.6% | -152.1% | ||
| Q2 24 | 32.2% | -327.6% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 30.0% | — | ||
| Q3 25 | 24.8% | -135.3% | ||
| Q2 25 | 25.1% | -186.2% | ||
| Q1 25 | 25.8% | -235.5% | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 20.0% | -142.7% | ||
| Q2 24 | 24.7% | -312.2% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.85 | — | ||
| Q3 25 | $0.69 | — | ||
| Q2 25 | $0.67 | $-0.33 | ||
| Q1 25 | $0.65 | $-0.36 | ||
| Q4 24 | $0.42 | $-0.24 | ||
| Q3 24 | $0.49 | $-0.28 | ||
| Q2 24 | $0.58 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $76.5M | — |
| Stockholders' EquityBook value | $593.9M | $698.6M |
| Total Assets | $7.5B | $913.2M |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $76.5M | — | ||
| Q4 25 | $76.5M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $131.5M | — | ||
| Q1 25 | $131.4M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $156.3M | — | ||
| Q2 24 | $156.2M | — |
| Q1 26 | $593.9M | — | ||
| Q4 25 | $592.6M | $698.6M | ||
| Q3 25 | $588.1M | $702.3M | ||
| Q2 25 | $568.9M | $698.5M | ||
| Q1 25 | $557.4M | $767.9M | ||
| Q4 24 | $538.4M | $710.4M | ||
| Q3 24 | $543.7M | $773.5M | ||
| Q2 24 | $518.6M | $768.5M |
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.4B | $913.2M | ||
| Q3 25 | $7.4B | $904.9M | ||
| Q2 25 | $7.4B | $907.4M | ||
| Q1 25 | $7.4B | $966.7M | ||
| Q4 24 | $7.5B | $910.4M | ||
| Q3 24 | $7.4B | $991.1M | ||
| Q2 24 | $7.4B | $964.3M |
| Q1 26 | 0.13× | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | $-52.6M | ||
| Q3 25 | $22.2M | $-78.7M | ||
| Q2 25 | $34.3M | $-67.4M | ||
| Q1 25 | $20.4M | $-103.7M | ||
| Q4 24 | $90.5M | $-73.3M | ||
| Q3 24 | $21.3M | $-59.0M | ||
| Q2 24 | $25.9M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $92.3M | $-61.9M | ||
| Q3 25 | $21.4M | $-89.5M | ||
| Q2 25 | $32.3M | $-74.9M | ||
| Q1 25 | $19.6M | $-109.9M | ||
| Q4 24 | $75.4M | $-77.5M | ||
| Q3 24 | $15.6M | $-61.3M | ||
| Q2 24 | $21.3M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 121.0% | -71.3% | ||
| Q3 25 | 28.6% | -132.7% | ||
| Q2 25 | 44.3% | -124.9% | ||
| Q1 25 | 28.4% | -222.8% | ||
| Q4 24 | 129.2% | -105.1% | ||
| Q3 24 | 23.5% | -104.6% | ||
| Q2 24 | 33.2% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 10.7% | ||
| Q3 25 | 1.2% | 16.1% | ||
| Q2 25 | 2.7% | 12.4% | ||
| Q1 25 | 1.3% | 12.6% | ||
| Q4 24 | 25.8% | 5.7% | ||
| Q3 24 | 8.5% | 3.9% | ||
| Q2 24 | 7.3% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 7.98× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CPF
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
